Miglustat Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

This orally active glucosylceramide glucosyltransferase inhibitor, was launched for the treatment of type I Gaucher’s disease. Miglustat (XVI) has been developed and launched by Oxford GlycoSciences (OGS; now Celltech) and Actelion.

Verwenden

Treatment of glycolipid storage diseases.

Miglustat Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Miglustat Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
SynZeal Research Pvt Ltd	--	standards@synzeal.com	India	6514	58
MYLAN API US LLC	--	jane.doe@mylan.com	India	44	58
Shanghai Qiming Biological Technology Co., Ltd.	--		CHINA	6502	58
Guangzhou Weijia Technology Co., Ltd.	--	WHIGA22@126.COM	CHINA	6748	58
Shanghai Chaoyan Biotechnology Co., Ltd.	--	471161314@qq.com	CHINA	6210	58
Saitong Biotechnology (Shanghai) Co., Ltd.	--	info@slk.cn	CHINA	9	58
Shanghai Hao Biological Technology Co., Ltd.	--	shxiyuanbio@163.com	CHINA	6906	58
Shanghai Zhenyu Biological Technology Co., Ltd.	--	2836767067@qq.com	CHINA	6970	58
Shanghai Yuda Industrial Co., Ltd.	--	lucy@runwelltac.com	CHINA	6105	58
Shanghai Hao Biological Technology Co., Ltd.	--	market@xlswkj.com	CHINA	6793	58

---

• Miglustat